ArticleInvestigative ophthalmology & visual science2000
Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
Article in Investigative ophthalmology & visual science, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 142 citations in OpenAlex.
- The Immunobiology of Dry Eye Disease: A Review of the Pathogenesis, Regulation and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Dual role of complement in neuronal repair.Frontiers in immunology · 2025Review
- CD3+CD4-CD8- Double-Negative Lymphocytes Are Increased in the Aqueous Humor of Patients with Retinitis Pigmentosa: Their Possible Role in Mediating Inflammation.International journal of molecular sciences · 2024Article
- The anterior chamber of the eye technology and its anatomical, optical, and immunological bases.Physiological reviews · 2024Review
- Complement regulation in the eye: implications for age-related macular degeneration.The Journal of clinical investigation · 2024Review
- Adipsin in the pathogenesis of cardiovascular diseases.Vascular pharmacology · 2024Review
- Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.Advanced drug delivery reviews · 2023Review
- Role of Complement in the Onset of Age-Related Macular Degeneration.Biomolecules · 2023Review
- Exploring the involvement of the alternative complement pathway in non-infectious uveitis pathogenesis.Frontiers in immunology · 2023Article
- Biological characteristics and pathogenicity ofFrontiers in microbiology · 2023Review
- Tear proteomics analysis of patient suffered from delayed mustard gas keratopathy.Proteome science · 2022Article
- Article
- Immunology and Donor-Specific Antibodies in Corneal Transplantation.Archivum immunologiae et therapiae experimentalis · 2021Review
- The cornea IV immunology, infection, neovascularization, and surgery chapter 1: Corneal immunology.Experimental eye research · 2021Review
- Transcriptomic and Histological Analysis of Exacerbated Immune Response in Multidrug-ResistantFrontiers in immunology · 2021Article
- Cytokine and Complement Response in the Glaucomatous βB1-CTGF Mouse Model.Frontiers in cellular neuroscience · 2021Article
- Corneal Allografts: Factors for and against Acceptance.Journal of immunology research · 2021Review
- Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021Review
- Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches.International journal of molecular sciences · 2020Review
- Risk factors for progression of age-related macular degeneration.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo explore the role of the complement system and complement regulatory proteins in an immune-privileged organ, the eye.
methodsEyes of normal Lewis rats were analyzed for the expression of complement regulatory proteins, membrane cofactor protein (MCP), decay-acceleration factor (DAF), membrane inhibitor of reactive lysis (MIRL, CD59), and cell surface regulator of complement (Crry), using immunohistochemistry, Western blot analysis, and reverse transcription-polymerase chain reaction (RT-PCR). Zymosan, a known activator of the alternative pathway of complement system was injected into the anterior chamber of the eye of Lewis rats. Animals were also injected intracamerally with 5 microl (25 microg) of neutralizing monoclonal antibody (mAb) against rat Crry (5I2) or CD59 (6D1) in an attempt to develop antibody induced anterior uveitis; control animals received 5 microl of sterile phosphate-buffered saline (PBS), OX-18 (25 microg), G-16-510E3 (25 microg), or MOPC-21 (25 microg). The role of complement system in antibody-induced uveitis was explored by intraperitoneal injection of 35 U cobra venom factor (CVF), 24 hours before antibody injection. Immunohistochemical staining and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Western blot analysis were used to detect the presence of membrane attack complex (MAC) and C3 activation products, respectively, in normal and antibody-injected rat eyes.
resultsComplement activation product MAC was present in the normal rat eye, and intraocular injection of zymosan induced severe anterior uveitis. The complement regulatory proteins, MCP, DAF, CD59, and Crry, were identified in the normal rat eye. Soluble forms of Crry and CD59 were also detected in normal rat aqueous humor. Severe anterior uveitis developed in Lewis rats injected with a neutralizing mAb against Crry, with increased formation of C3 split products. Systemic complement depletion by CVF prevented the induction of anterior uveitis by anti-Crry mAb. Intracameral injection of anti-rat CD59 (6D1), anti-rat MHC class I antigen (OX-18), anti-rat Ig (G-16-510E3), or MOPC-21 caused no inflammatory reaction.
conclusionsThe results suggest that the complement system is continuously active at a low level in the normal eye and is tightly regulated by intraocular complement regulatory proteins.
Indexed as
Identifiers
11006244PMC1851917W1593976080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.